Relevant bibliographies by topics / RHuEPO

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'RHuEPO'

Author: Grafiati
Published: 4 June 2021
Last updated: 6 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'RHuEPO.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "RHuEPO"

1

Fibi, MR, P. Hermentin, JU Pauly, L. Lauffer, and G. Zettlmeissl. "N- and O-glycosylation muteins of recombinant human erythropoietin secreted from BHK-21 cells." Blood 85, no. 5 (1995): 1229–36. http://dx.doi.org/10.1182/blood.v85.5.1229.bloodjournal8551229.

Full text
Abstract:
Single-site glycomuteins of recombinant human erythropoietin (rhuEpo) were constructed and transiently and stably expressed in BHK-21 cells. The transient expression levels varied among muteins, being highest for mutein rhuEpoGln24 followed by wild-type rhuEpo (rhuEpowt). All other glycomuteins, including rhuEpoGln38, rhuEpoGln83, rhuEpoThr126, and rhuEpoGly126, were secreted at lower levels than rhuEpowt. Muteins expressed in stable cell lines showed similar differences in expression levels. Also each mutein could be affinity-purified from culture supernatants, and was biologically active in
APA, Harvard, Vancouver, ISO, and other styles
2

Aguilera, Abelardo, Rafael Selgas, M. Luisa Ruiz-Caravaca, et al. "Effects of Recombinant Human Erythropoietin on Functional and Injury Endothelial Markers in Peritoneal Dialysis Patients." Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis 19, no. 2_suppl (1999): 161–66. http://dx.doi.org/10.1177/089686089901902s25.

Full text
Abstract:
Clinical effects of recombinant human erythropoietin (rHuEPO) such as thrombosis, convulsions, hyperviscosity, hypertension, and angiogenic effect in culture cells have been described. We studied the rHuEPO effect on endothelial damage markers and endothelial function markers: tissue-type plasminogen activator (t-PA), nitrate (NO3), thrombomodulin (TM), and von Willebrand factor (vWF). Twenty-six peritoneal dialysis patients treated with rHuEPO and 19 controls were included. The study design for rHuEPO patients consisted of four periods: long-term treatment (rHuEPO-1); 2 months of withdrawal (
APA, Harvard, Vancouver, ISO, and other styles
3

Bajo, Maria Auxiliadora, Rafael Selgas, Maria Jose Castro, et al. "Erythropoietin Treatment Decreases Cardiovascular Morbidity and Mortality in Capd Patients." Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis 17, no. 2 (1997): 129–35. http://dx.doi.org/10.1177/089686089701700206.

Full text
Abstract:
Objective To analyze the effects of recombinant human erythropoietin (rHuEPO) therapy on cardiovascular (CV) morbidity and mortality among continuous ambulatory peritoneal dialysis (CAPD) patients. Design Retrospective comparative study. Setting CAPD unit in a university hospital. Patients Forty-two patients on rHuEPO treatment for at least one year were compared with an rHuEPO nonuser group of 113 patients. Subcutaneous rHuEPO doses were adjusted to a hemoglobin objective level of 10.5 -13.5 g/ dL. Fifty-seven patients were considered as high cardiovascular risk (HCVR), 17 in the rHuEPO group
APA, Harvard, Vancouver, ISO, and other styles
4

Katz, Odelia, Nataliya Golishevski, Howard S. Oster, et al. "Improved Glycemic Control in Diabetic Patients Treated with Recombinant Human Erythropoietin." Blood 108, no. 11 (2006): 4228. http://dx.doi.org/10.1182/blood.v108.11.4228.4228.

Full text
Abstract:
Abstract Recombinant human erythropoietin (rHuEPO) originally used to treat anemia has also been found to have several pleiotropic actions, e.g. neuroprotection, cardioprotection, and immune effects. Based on our preliminary data in mice, and on the studies by others of reduced insulin resistance in rHuEPO-treated hemodialysis patients, we have raised the question of a potential association between EPO and glycemic control. Here we report our observation of glucose control in four rHuEPO-treated diabetic patients. These diabetic patients were treated with rHuEPO for their anemia associated wit
APA, Harvard, Vancouver, ISO, and other styles
5

Vorobiov, Marina, Myriam Malki, Alla Shnaider, et al. "Erythropoietin Prevents Dialysis Fluid-Induced Apoptosis of Mesothelial Cells." Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis 28, no. 6 (2008): 648–54. http://dx.doi.org/10.1177/089686080802800618.

Full text
Abstract:
Background In peritoneal dialysis (PD)-treated patients, denudation of the mesothelium correlates with peritoneal fibrosis and vascular changes. Since recombinant human erythropoietin (rHuEPO) induces a range of cytoprotective cellular responses, rHuEPO treatment may reduce PD fluid (PDF)-induced damage. Methods To investigate the antiapoptotic effect and mechanism of rHuEPO in peritoneal mesothelial cells (PMCs), isolated mice PMCs were used for in vitro characterization of rHuEPO effects. To confirm the in vitro effects, active caspase-3 was analyzed in imprints of liver visceral peritoneum
APA, Harvard, Vancouver, ISO, and other styles
6

Elliott, S., D. Chang, E. Delorme, et al. "Isolation and characterization of conformation sensitive antierythropoietin monoclonal antibodies: effect of disulfide bonds and carbohydrate on recombinant human erythropoietin structure." Blood 87, no. 7 (1996): 2714–22. http://dx.doi.org/10.1182/blood.v87.7.2714.bloodjournal8772714.

Full text
Abstract:
We have isolated and characterized three anti-recombinant human erythropoietin (rHuEPO) monoclonal antibodies (MoAbs) that recognize nonoverlapping epitopes on rHuEPO. Anti-EPO MoAb D11 neutralizes rHuEPO activity whereas MoAbs F12 and 9G8A do not. This suggests that D11 may bind to the rHuEPO active site. MoAbs F12 and D11 recognize conformation dependent epitopes whereas 9G8A does not. Immunoassays were developed for each monoclonal. The 9G8A immunoassay was novel and useful because immunoreactivity increased when rHuEPO was denatured. Disruption of disulfide bonds or removal of carbohydrate
APA, Harvard, Vancouver, ISO, and other styles
7

Takemasa, A., N. Yorioka, and M. Yamakido. "Stimulation of Interleukin-1 ß Production may be Involved in Unresponsiveness to Erythropoietin Therapy." International Journal of Artificial Organs 19, no. 11 (1996): 633–37. http://dx.doi.org/10.1177/039139889601901103.

Full text
Abstract:
Recombinant human erythropoietin (rHuEPO) can dramatically improve anemia in dialysis patients, but about 20% of patients show a poor response to this agent. It has been reported that cytokines, including interleukin (IL)-1ß, may inhibit the maturation of erythrocytes. To investigate the mechanisms of unresponsiveness to rHuEPO, we isolated peripheral blood mononuclear cells from 12 patients on continuous ambulatory peritoneal dialysis who were receiving maintenance rHuEPO therapy for renal anemia. Cells were cultured with rHuEPO and IL-1 ß production was assessed. In the six patients who did
APA, Harvard, Vancouver, ISO, and other styles
8

Salahudeen, Abdulla K., Naeem Haider, John Jenkins, et al. "Antiapoptotic properties of erythropoiesis-stimulating proteins in models of cisplatin-induced acute kidney injury." American Journal of Physiology-Renal Physiology 294, no. 6 (2008): F1354—F1365. http://dx.doi.org/10.1152/ajprenal.00131.2008.

Full text
Abstract:
Erythropoietin (Epo) induces erythrocytosis by suppressing erythroid progenitor cell apoptosis through the Janus-activated kinase-signal transducers and activators of transcription (JAK-STAT) pathway. Since apoptosis contributes to cisplatin (CP)-induced nephrotoxicity and Epo receptors (EpoR) are expressed in the kidney, we examined the role of antiapoptosis in recombinant human erythropoietin (rHuEpo)-mediated renal protection. In human renal proximal tubular epithelial (RPTE) cells in culture, rHuEpo, but not inactive rHuEpo (I-rHuEpo), the receptor-binding sites of which are mutated, cause
APA, Harvard, Vancouver, ISO, and other styles
9

Oster, Howard S., Moran Gvili, Odelia Katz, Michael Hoffman, Drorit Neumann, and Moshe Mittelman. "Erythropoietin Treatment Is Associated with Decreased Blood Glucose Levels: A Preliminary Study in Hematologic Patients." Blood 118, no. 21 (2011): 4793. http://dx.doi.org/10.1182/blood.v118.21.4793.4793.

Full text
Abstract:
Abstract Abstract 4793 Introduction: Erythropoietin (EPO) is the major hormone which enhances proliferation and maturation of the red cell lineage, and its recombinant form (rHuEPO) is used extensively to treat various types of anemia. rHuEPO has also been found to exert effects in other organ systems, and our previous work has demonstrated an immunomodulatory role for EPO. Recently, we have also found that mice exposed to high levels of EPO (either rHuEPO injections or transgenic mice overexpressing human EPO), have significantly lower levels of blood glucose than those of their respective co
APA, Harvard, Vancouver, ISO, and other styles
10

Fernandes, J. C., P. Garrido, S. Ribeiro, et al. "Iron as the Key Modulator of Hepcidin Expression in Erythroid Antibody-Mediated Hypoplasia." BioMed Research International 2014 (2014): 1–10. http://dx.doi.org/10.1155/2014/421304.

Full text
Abstract:
Erythroid hypoplasia (EH) is a rare complication associated with recombinant human erythropoietin (rHuEPO) therapies, due to development of anti-rHuEPO antibodies; however, the underlying mechanisms remain poorly clarified. Our aim was to manage a rat model of antibody-mediated EH induced by rHuEPO and study the impact on iron metabolism and erythropoiesis. Wistar rats treated during 9 weeks with a high rHuEPO dose (200 IU) developed EH, as shown by anemia, reduced erythroblasts, reticulocytopenia, and plasmatic anti-rHuEPO antibodies. Serum iron was increased and associated with mRNA overexpr
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "RHuEPO"

1

Hedenberg, Jennifer. "Hur rHuEPO kan påverka uthållighetsprestanda." Thesis, Uppsala universitet, Institutionen för farmaceutisk biovetenskap, 2020. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-412038.

Full text
Abstract:
Erytropoietin (EPO) är ett endogent glykoproteinhormon som stimulerar produktionen av erytrocyter. Erytrocyternas huvuduppgift är att transportera syre till vävnader och på detta sätt främja aerob metabolism vilket genererar energi till musklerna. På 80-talet framställdes för första gången rekombinant humant EPO (rHuEPO) vilket på senare år använts illegalt som dopingmedel. Denna typ av doping klassas följaktligen som bloddoping och 1990 förbjöds rHuEPO av World Anti-Doping Agency (WADA). Många fall av rHuEPO doping har emellertid uppdagats under åren där syftet med användningen hos atleterna
APA, Harvard, Vancouver, ISO, and other styles
2

Collares, Thais Farias. "Desenvolvimento de ensaio imunoquímico para detecção de doping com eritropoetina." Universidade Federal de Pelotas, 2013. http://guaiaca.ufpel.edu.br/handle/123456789/1225.

Full text
Abstract:
Made available in DSpace on 2014-08-20T13:32:48Z (GMT). No. of bitstreams: 1 tese_thais_farias_collares.pdf: 1094762 bytes, checksum: 647dd933472bf9127c0164ee875617ea (MD5) Previous issue date: 2013-10-17<br>The history of sports competition has been related to the use of methods for physical training associated with physiological methods to increase athlete performance. Ethical issues involving the high performance sport and doping are confused with the history of competitive sports. The World Anti - Doping Agency (WADA) prohibits the use of substances or methods to artificially increase
APA, Harvard, Vancouver, ISO, and other styles
3

Crowell, Christopher Kenyon. "Depleted amino acids and sodium butyate [sic] alter the phenotype and genotype of cell lines expressing rHuEPO /." Connect to full text via ProQuest. Limited to UCD Anschutz Medical Campus, 2006.

Find full text
Abstract:
Thesis (Ph.D. in Pharmaceutical Sciences) -- University of Colorado at Denver and Health Sciences Center, 2006.<br>Typescript. Includes bibliographical references (leaves 133-142). Free to UCDHSC affiliates. Online version available via ProQuest Digital Dissertations;
APA, Harvard, Vancouver, ISO, and other styles
4

Martínez, Bello Vladimir Essau. "Efectos musculares y hematológicos del uso de rHuEpo en combinación con el entrenamiento físico. Implicaciones de la demospresina y la hipoxia en el dopaje sanguineo. Estudios in vivo e in vitro." Doctoral thesis, Universitat de València, 2011. http://hdl.handle.net/10803/78993.

Full text
Abstract:
En la presente Tesis Doctoral hemos querido estudiar, en primer lugar, el efecto que tendría el incremento artificial de la capacidad de transporte de oxígeno, a través del tratamiento con rHuEpo, sobre distintos parámetros musculares así como su implicación en la mejora del rendimiento físico. Son muchos los autores que, tanto en el ámbito clínico (Winearls, Oliver y cols. 1986; Bommer, Muller-Buhl y cols. 1987) como en el ámbito deportivo (Berglund y Ekblom 1991; Lundby, Robach y cols. 2008), han destacado que los beneficios alcanzados con los tratamientos con Epo desbordan con creces su pap
APA, Harvard, Vancouver, ISO, and other styles
5

Collares, Thais Farias. "Efeito da administração de eritropoetina e de vetores recombinantes em parâmetros reprodutivos de coelhos." Universidade Federal de Pelotas, 2010. http://repositorio.ufpel.edu.br/handle/ri/1279.

Full text
Abstract:
Made available in DSpace on 2014-08-20T13:32:56Z (GMT). No. of bitstreams: 1 dissertacao_thais_farias_collares.pdf: 421000 bytes, checksum: d922362fc9456c8a75d15a49744bf882 (MD5) Previous issue date: 2010-05-28<br>The administration of recombinant proteins is being used in sport as gene doping. In medicine, a recent therapeutic technique is the genetic therapy, which, up to this moment, shows results that indicate its efficiency in the treatment of some diseases. Recently, the potential for misuse of gene therapy among athletes has called the attention of scientists and sports regulating o
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "RHuEPO"

1

Puñña, Maṅʻʺ. Nanʻʺ tvaṅʻʺ ʼa rhupʻ toʻ puṃ nhaṅʻʹ pugguilʻ myāʺ. Laṅʻʺ Laṅʻʺ Cā pe, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Hoek-Smit, Marja. An evaluation of East and Southern Africa RHUDO training. Community Consulting Group, International, 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Miller, John D. Evaluation: RHUDO/South America Training Program, Latin American Center for Urban Management. Abt Associates, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

United States. Agency for International Development. Outline of housing finance systems and delivery mechanisms, Paraguay: A report for the USAID Regional Housing and Urban Development Office for South America (RHUDO/SA) Quito, Ecuador. Cooperative Housing Foundation, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Chve, Nanʻʺ Ññvanʻʹ. Mranʻ mā Praññʻ jātʻ lamʻʺ rhupʻ sa myha loka jātʻ khuṃ ʼa phuṃ phuṃ ʼa lī lī: Cā pe, yañʻ kyeʺ mhu, nuiṅʻ ṅaṃ reʺ, bhava ʼa tveʹ ʼa kruṃ. Saṅʻʺ Cā pe, 2013.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Sa taṅʻʺ thokʻ krīʺ Ūʺ Lū Rhupʻ. Kaṃ Khyvanʻ Cā pe tuikʻ, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Tractorau: Gwasga'r botwm i glywed yr injan yn rhuo!. Gomer, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Grand Opera House, London, Ont., programme: Saturday, Nov. 7th, Mr. Joseph Murphy supported by his own company Shaun Rhue .. s.n., 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Grand Opera House, London, Ont., programme: Friday, Feb. 22nd, special engagement of the legitimate Irish comedian Mr. Joseph Murphy, supported by his own company in the Shaun Rhue .. s.n., 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Cvā, Rai khoṅʻ Kyoʻ, ред. Ūʺ Nu praññʻ preʺ bhava ka bhā tve phracʻ khaiʹ sa lai, bhā tve lupʻ khaiʹ sa lai: Ūʺ Nu mha Praññʻ thai reʺ Vanʻ krīʺ Ṭhāna suiʹ ʼapʻ nhaṃ khaiʹ so praññʻ preʺ bhava ʼa tvaṅʻʺ reʺ ʼa rhupʻ toʻ puṃ cā rvakʻ cā tamʻʺ myāʺ. Pranʻ krāʺ reʺ Ṭhāna, Sa taṅʻʺ nhaṅʻʹ Cā nayʻ jaṅʻʺ Lupʻ ṅanʻʺ, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "RHuEPO"

1

Mercuriali, Francesco, and G. Inghilleri. "rHuEPO in surgical oncology." In Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology. Springer Vienna, 2002. http://dx.doi.org/10.1007/978-3-7091-7658-0_19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Buemi, M., C. Alosi, M. Morabito, et al. "Effects of rHuEPO on the Aldosterone Secretion." In New Therapeutic Strategies in Nephrology. Springer US, 1991. http://dx.doi.org/10.1007/978-1-4615-3884-4_65.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Lamperi, S., S. Carozzi, A. Icardi, M. G. Nasini, and G. B. Traverso. "Treatment of Uremic Anemia with Etretinate: Comparison with Recombinant Human Erythropoietin (rHuEPO)." In Current Therapy in Nephrology. Springer US, 1989. http://dx.doi.org/10.1007/978-1-4613-0865-2_41.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Ruiz, L. M., J. Ocharan, G. García-Erauzkin, et al. "Comparative Efficacy of Two Different Intravenous Dosages of Recombinant Human Erythropoietin (rHuEPO) in the Anemia of Haemodialysis. Effects on Iron Stores." In New Therapeutic Strategies in Nephrology. Springer US, 1991. http://dx.doi.org/10.1007/978-1-4615-3884-4_90.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

"Recombinant Human Erythropoietin (rHuEpo and Darbepoetin alfa)." In Handbook of Disease Burdens and Quality of Life Measures. Springer New York, 2010. http://dx.doi.org/10.1007/978-0-387-78665-0_6523.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Stivelman, John C. "Refractoriness to Recombinant Human Epoetin (rHuEPO) Treatment." In Handbook of Dialysis Therapy. Elsevier, 2008. http://dx.doi.org/10.1016/b978-1-4160-4197-9.50067-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

CARTEI, F., A. SAINATO, M. MIGNOGNA, A. PASQUARIELLO, and M. LADDAGA. "IRRADIATION AND ERYTHROPOIETIN (rHuEPO) IN TREATMENT OF CANCER." In Radiation Research: A Twentieth-century Perspective. Elsevier, 1991. http://dx.doi.org/10.1016/b978-0-12-168561-4.50310-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Karypidis, Dimitrios, Despina Perrea, Othon Papadopoulos, and Alkiviadis Kostakis. "The Effect of Human Recombinant Erythropoietin (rHuEPO) and Tacrolimus (FK506) in Autologous and Homologous Full Thickness Skin Graft (FTSG) Take and Viability in a Rat Model." In Skin Grafts - Indications, Applications and Current Research. InTech, 2011. http://dx.doi.org/10.5772/21946.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "RHuEPO"

1

Moia, M., S. Casati, P. Della Valle, P. Passerini, C. Ponticelli, and P. M. Mannucci. "HUMAN RECOMBINANT ERYTHROPOIETIN (rHuEpo) CORRECTS ANEMIA AND SHORTENS THE BLEEDING TIME (BT) IN UREMIC PATIENTS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644749.

Full text
Abstract:
A hemorrhagic tendency and anemia are two major complications of uremia. There is a significant negative correlation between BT and hematocrit (Ht) in uremic patients. We studied the efficacy of rHuEpo in correcting both these abnormalities in 10 patients on chronic hemodialysis with severe anemia (basal Hb levels 6.2±0.8 g/dL). Seven patients had BT longer than 10 min., 5 had BT longer than 30 min. rHuEpo was given to the patients 3 times a week at increasing doses, from 24 U/Kg to a maximum of 432 U/Kg, aiming to reach Hb levels ⪖12 g/dL. BT was measured (with the template-like disposable de
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'RHuEPO' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography